Carcinoma: all 6,718 studies

Page 31 of 68. Open to participants first (1,141), then studies with results posted, then the rest; newest registration first within each.

• Combined Aerobic and Resistance Exercise Training in Metastatic Renal Cell CarcinomaTerminatedNCT05103722Not applicable
• Salvage Immunotherapy and Chemotherapy in Esophageal Squamous Cell Carcinoma Patients Nonresponding to Initial Neoadjuvant ChemoradiotherapyStatus unknownNCT05103501Phase 2
• Asian Multicenter Prospective Study of ctDNA SequencingActive, not recruitingNCT05099978
• Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing CancersTerminatedNCT05099549Phase 1/2
• Role of DEB-TACE Versus c-TACE in Treatment of HCCStatus unknownNCT05093920Early Phase 1
• SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular CarcinomaTerminatedNCT05093608Phase 1
• SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast CancerWithdrawnNCT05093387Phase 1
• Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal CarcinomaStatus unknownNCT05092217Phase 2
• The Role of Long Non-coding RNAs WRAP53 and UCA-1 as Potential Biomarkers in Diagnosis of Hepatocellular CarcinomaStatus unknownNCT05088811
• Yang Yin Fu Zheng Jie Du Therapy in HBV Related Hepatocellular Carcinoma Induced Anemia (YYFZJDTIHBVRHCIA)Status unknownNCT05088733Early Phase 1
• Treatment of Avatrombopag for Thrombocytopenia in Patients Undergoing Selective Resection of Hepatocellular CarcinomaStatus unknownNCT05087459
• Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast CancerCompletedNCT05086731Not applicable
• A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547Status unknownNCT05086666Phase 1/2
• Psychological, Psychophysical and Epigenetic Determinants of Chronic Pain After Cytoreductive - Hyperthermic Intraoperative ChemotherapyCompletedNCT05083338
• Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine CarcinomaStatus unknownNCT05076786Phase 2
• Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With PembrolizumabStatus unknownNCT05075122Phase 2
• StrataXRT for the Prevention and Treatment of Radiation Dermatitis in Breast Cancer or Head and Neck Cancer PatientsWithdrawnNCT05073172Not applicable
• Treatment Decision Making in African American Women Diagnosed With Triple Negative Breast CancerCompletedNCT05071677
• Circulating Tumor Cell Reducing No-touch NephrectomyCompletedNCT05070637Not applicable
• B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular CarcinomaActive, not recruitingNCT05070156Early Phase 1
• Value of Cortactin Expression in Invasive and Non-invasive Urinary Bladder Urothelial Carcinoma in Egyptian PopulationCompletedNCT05070039Not applicable
• A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO)CompletedNCT05068609
• A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking EzabenlimabActive, not recruitingNCT05068102Phase 1
• Role of Perfluorobutane in Lesion Detection, Targeting and Response Assessment for Ablation of HCCCompletedNCT05068076Not applicable
• Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic CancerTerminatedNCT05065736Early Phase 1
• A Real-world Study of the Safety and Efficacy of Surufatinib in the Treatment of Biliary Tract CarcinomaStatus unknownNCT05064852
• Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the CervixActive, not recruitingNCT05063916Phase 2
• TheraSphere With Durvalumab and Tremelimumab for HCCActive, not recruitingNCT05063565Phase 2
• Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck CancersActive, not recruitingNCT05063552Phase 2/3
• Role of Magnetic Resonance Enterography for Predicting Peritoneal Cancer IndexStatus unknownNCT05063019Not applicable
• This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.TerminatedNCT05061940
• PD-1 Blockade Combined with Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA PatientsCompletedNCT05060471Phase 2
• Personalized Cancer Vaccine in Egyptian Cancer PatientsStatus unknownNCT05059821Phase 1
• Performance Evaluation (Sensitivity/Specificity) of HelioLiver Test for Detection of HCCCompletedNCT05059665
• Non-inferiority Study of Unresectable Hepatocelluar Carcinoma Receiving Stereotactic Radiotherapy Combined With Hepatic Arterial Chemoembolization Compared With Conversion HepatectomyStatus unknownNCT05057104
• Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCCStatus unknownNCT05056337Phase 3
• Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular CarcinomaStatus unknownNCT05053386Not applicable
• Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving ErdafitinibTerminatedNCT05052372
• Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck CancerActive, not recruitingNCT05050162Phase 2/3
• The Clinicopathological and Prognostic Factors of Hepatocellular Carcinoma; 10 Years' Tertiary Center Experience in EgyptCompletedNCT05047146
• Calcium Electroporation for Basal Cell Carcinomas - Proof of Concept StudyStatus unknownNCT05046262Phase 3
• Pathological Results of Aggressive Hepatocellular Carcinomas Treated Using SIRTCompletedNCT05045573
• Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCCActive, not recruitingNCT05043090Phase 3
• The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCCStatus unknownNCT05042336Phase 1/2
• Predictive Imaging Features in Renal Cell CarcinomaCompletedNCT05042089
• Optical-Coherence Tomography for the Non-invasive Diagnosis and Subtyping of Basal Cell CarcinomaStatus unknownNCT05041777
• Natural Killer (NK) Cell Therapy in Locally Advanced HCCCompletedNCT05040438Phase 2
• Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC)Active, not recruitingNCT05038813Phase 2
• Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC).Status unknownNCT05038657Phase 2
• A Study to Evaluate Efficacy and Safety of TheraSphere and Resection Combination Therapy in Patients With Single Large ((> 5cm, Long Diameter ) Hepatocellular Carcinoma : Exploratory TrialCompletedNCT05038397Not applicable
• Gallium-68 PSMA-11 PET in Participants With Prostate CancerWithdrawnNCT05034562Phase 2
• Subzero and Scorpion TrialWithdrawnNCT05032079Not applicable
• A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary MalignanciesActive, not recruitingNCT05032040Phase 2
• Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal CancerStatus unknownNCT05030246Phase 2
• Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial CarcinomaStatus unknownNCT05030077Phase 2
• HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCCStatus unknownNCT05029973Phase 2
• Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical StudyStatus unknownNCT05028231
• En Bloc TURBT With Collins Loop vs Conventional TURBTStatus unknownNCT05027412Not applicable
• A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN)Status unknownNCT05027204Phase 1/2
• Real-World Effectiveness of Regorafenib in the Treatment of Patients With Hepatocellular CarcinomaStatus unknownNCT05024539
• Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell CarcinomaStatus unknownNCT05024266Phase 2
• GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTCActive, not recruitingNCT05023109Phase 2
• A Phase I Study of ERY974 in Patients With Hepatocellular CarcinomaActive, not recruitingNCT05022927Phase 1
• Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME StudyWithdrawnNCT05022394Phase 1/2
• SBRT With DIBH for HCC After TACE and Lipiodol MarkingActive, not recruitingNCT05021250Not applicable
• Incorporating ePrognosis for the Encouragement of Smarter Screening for Breast and Colorectal Cancer in Older AdultsCompletedNCT05021172Not applicable
• SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT05020925Phase 1/2
• Impact on Xerostomia for Nasopharyngeal Carcinoma Patients Treated With or Without Superficial Parotid Lobe-sparing Intensity-modulated RadiotherapyCompletedNCT05020067Phase 2
• Study of the Association Between Tumor Microenvironment Macrophages and Treatment Response in Squamous Cell Carcinoma of the Anal CanalStatus unknownNCT05019235
• Efficacy of TACE With Endoscopic Therapy for Unresectable Hepatocellular CarcinomaCompletedNCT05017922Not applicable
• Efficacy and Safety of Neoadjuvant Surufatinib for Patients With Salivary Gland CarcinomasStatus unknownNCT05013515Not applicable
• Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical CarcinomaStatus unknownNCT05013268Phase 1
• Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic MalignanciesActive, not recruitingNCT05013099Phase 2
• An Episodic Future Thinking Intervention to Promote Weight Loss in Breast Cancer SurvivorsCompletedNCT05012176Not applicable
• Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular CarcinomaActive, not recruitingNCT05010434Phase 2
• Application of Whole-course Standardized Nutrition Management During Peri-radiotherapy in Patients With Nasopharyngeal Carcinoma After Radiotherapy: a Multicenter Randomized Controlled Clinical StudyStatus unknownNCT05008471Not applicable
• Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT05007613Phase 2
• Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCCStatus unknownNCT05007587Early Phase 1
• PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaStatus unknownNCT05007145Phase 2
• Radiofrequency Ablation for the Treatment of Benign or Low Risk Thyroid NoduleTerminatedNCT05003856Not applicable
• Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular CarcinomaCompletedNCT05003700Phase 2
• 68Ga-FAPI-04 PET/CT for the Detection of Oral CarcinomaStatus unknownNCT05003427Early Phase 1
• Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)CompletedNCT04996758Phase 2
• Tislelizumab in the Systematic Treatment of Advanced Hepatocellular CarcinomaStatus unknownNCT04996459
• 18F-FMISO PET Guided Dose Escalation in Nasopharyngeal Carcinoma - a Feasibility and Planning StudyCompletedNCT04995185Not applicable
• Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell CarcinomaStatus unknownNCT04995016Phase 2
• Hepatic Artery Infusion Chemotherapy for Unresectable Hepatocelluar Carcinoma Who Failed to Systemic TherapyStatus unknownNCT04994236Phase 2
• Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II TrialStatus unknownNCT04992988Phase 2
• Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung CancerWithdrawnNCT04989283Phase 2
• GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer PatientsWithdrawnNCT04987996Phase 2
• Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell CarcinomaWithdrawnNCT04985825Phase 2
• Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to DrugsWithdrawnNCT04985357
• A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)TerminatedNCT04985136Phase 3
• Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 BlockadeStatus unknownNCT04984018Phase 2
• A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative ResectionStatus unknownNCT04981665Phase 2
• An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate CancerCompletedNCT04978675Phase 1
• Efficacy and Safety of TACE in Combination With ICIs for HCC: a Real-world StudyCompletedNCT04975932
• A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT04974398Phase 3
• PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCCStatus unknownNCT04974281Early Phase 1
• Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular CarcinomaStatus unknownNCT04973098Phase 1

← Carcinoma overview